{"id":98953,"date":"2026-10-29T10:00:00","date_gmt":"2026-10-29T14:00:00","guid":{"rendered":"https:\/\/www.rxbriefcase.com\/rxbriefly-item\/%f0%9f%a7%9f-the-cells-that-refuse-to-die\/"},"modified":"2026-10-29T10:00:00","modified_gmt":"2026-10-29T14:00:00","slug":"%f0%9f%a7%9f-the-cells-that-refuse-to-die","status":"publish","type":"rxbriefly","link":"https:\/\/www.rxbriefcase.com\/fr\/rxbriefly-item\/%f0%9f%a7%9f-the-cells-that-refuse-to-die\/","title":{"rendered":"\ud83e\udddf The cells that refuse to die"},"content":{"rendered":"
\n
\n
\"\"<\/a><\/div>\n

Good morning, dispensers of wisdom!<\/b><\/p>\n

If we’ve learned anything from horror movies, it’s that the dead ought to stay dead. A lesson we can apply to new research on zombie-like cancer cells. These cells survive chemotherapy by entering a senescent state, meaning they stop dividing but don’t die. Instead, they can grow up to 10 times larger than normal and release signals that hijack the body’s healing responses. The good news? Researchers discovered<\/a> that these stubborn survivors rely on proteins called IAPs, and blocking them killed the cells in laboratory experiments. A potential way to finally put these zombies to rest.<\/p>\n

Let’s get into it.<\/p>\n

\n

Staying #Up2Date <\/span>🚨<\/h1>\n<\/div>\n
\n

1: Smoking vs. Vaping Like a Chimney?<\/b><\/p>\n

A cross-sectional study<\/i><\/a> of 58 young adults found that nicotine vaping was associated with impaired vascular function and cardiorespiratory fitness. Both flow-mediated dilation and carotid artery reactivity were reduced among those who vaped, with similar vascular impairments seen in cigarette smokers. Vapers also had lower peak oxygen uptake than those who had never smoked or vaped. A larger longitudinal study is needed to determine how vaping stacks up to cigarettes over time.<\/p>\n

2: A Surprising Twist for Empagliflozin<\/b><\/p>\n

SGLT2 inhibitors have earned a reputation for protecting the kidneys, but does that benefit extend to every kidney disease? A new randomized trial<\/a> involving 50 adults with autosomal dominant polycystic kidney disease found that patients taking empagliflozin experienced a greater increase in kidney volume over 12 months than those receiving placebo (10.5% vs. 5.1% annually). The medication was generally well tolerated, with no significant difference in longer-term kidney function decline. It’s a small study, but the findings raise questions about whether SGLT2 inhibitors offer the same benefits across different kidney conditions.<\/p>\n

3: A New Weapon Against Prostate Cancer?<\/b><\/p>\n

Could adding another medication to standard treatment help prevent aggressive prostate cancer from spreading? An international Phase 3 trial highlighted by McGill University<\/a> suggests it could. Involving more than 1,100 patients, the study found that adding darolutamide to standard therapy reduced the risk of cancer spreading in men with very high-risk prostate cancer. The findings could help shape future treatment recommendations, although longer follow-up is needed to determine whether the benefit translates into improved overall survival.<\/p>\n<\/div>\n

\n

Are You Seeing Patients With Recurring Dandruff & Scalp Seborrheic Dermatitis? <\/span><\/h1>\n<\/div>\n
\n

Dandruff and scalp seborrheic dermatitis (SSD) are chronic and relapsing, and symptoms can return once treatment stops. So, what happens after the dandruff flakes ease and the flare settles?<\/p>\n

\"\"<\/div>\n

A study in 48 adults with moderate-to-severe scalp seborrheic dermatitis explored a selenium disulfide shampoo as maintenance after topical corticosteroid\/salicylic acid treatment, with fewer relapses than the vehicle shampoo over eight weeks.<\/p>\n

Take a Closer Look <\/span><\/a><\/div>\n<\/div>\n
\n

Shelf Watch <\/span>🏥<\/h1>\n<\/div>\n
\n

Drug Shortages <\/b><\/span>🚫<\/p>\n

Diclofenac Potassium<\/a><\/p>\n